- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes
Episode 17 of the Patient Care Online Primary Viewpoints podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Primary Viewpoints podcast features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today.
In episode 17, Dr Hiddo Heerspink, joins us to discuss findings he recently presented at the American Diabetes Association 2022 Scientific Sessions from a pre-specified analysis he led of the SURPASS-4 clinical trial of tirzepatide that looked for the first time at the effects of the novel GLP-1 receptor agonist on kidney function in patients with type 2 diabetes.
Hiddo Heerspink, PhD, PharmD, is professor of clinical trials and personalized medicine and a clinical pharmacologist/trialist in the department of clinical pharmacy and pharmacology at the University Medical Center Groningen in Groningen, Netherlands; he is also Codirector of the Better Treatments Program at the George Institute for Global Health in Newtown, Australia.
Click here to subscribe to the Primary Viewpoints podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?
May 8th 2013The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?
